Hanmi Announces 4th Major Deal: Janssen Acquires Diabetes Drug for $960 Million

Hanmi Pharma of South Korea announced another blockbuster out-licensing deal for one of its clinical stage assets. This time, Janssen agreed to a $960 million deal in exchange for exclusive worldwide rights (except Korea and China) to a novel biologic GLP-1/Glucagon dual receptor agonist aimed at diabetes and obesity. The molecule, HM12525A, is expected to begin Phase II trials next year. Last week, Sanofi agreed to pay as much as $4.2 billion for three Hanmi long-acting diabetes drugs. More details.... Stock Symbols: (KRX: 1289400) (NYSE: SNY) Share this with colleagues: // //